Emerging cell and molecular targets for treating mucus hypersecretion in asthma
Allergology International · 2024-07 · 73 (3) · 375-381
DOI: 10.1016/j.alit.2024.04.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Allergology International, 2024-07. Verfasst von Ana M Jaramillo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora, CO, USA. Hauptthemen laut MEDLINE: Asthma, Mucus. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 168 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BLRD VA, NHLBI NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Mucus provides a protective barrier that is crucial for host defense in the lungs. However, excessive or abnormal mucus can have pathophysiological consequences in many pulmonary diseases, including asthma. Patients with asthma are treated with agents that relax airway smooth muscle and reduce airway inflammation, but responses are often inadequate. In part, this is due to the inability of existing therapeutic agents to directly target mucus. Accordingly, there is a critical need to better understand how mucus hypersecretion and airway plugging are affected by the epithelial cells that synthesize, secrete, and transport mucus components. This review highlights recent advances in the biology of mucin glycoproteins with a specific focus on MUC5AC and MUC5B, the chief macromolecular components of airway mucus. An improved mechanistic understanding of key steps in mucin production and secretion will help reveal novel potential therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
- Department of Pulmonary Medicine, Anderson Cancer Center, University of Texas M.D., Houston, TX, USA.
- Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora, CO, USA. Electronic address: christopher.evans@cuanschutz.edu.
Förderung
- BLRD VA
- NHLBI NIH HHS
- NIAID NIH HHS
- National Institutes of Health
- US Department of Veterans Affairs
Zitieren
APA
Jaramillo, A. M., Vladar, E. K., Holguin, F., Dickey, B. F., & Evans, C. M. (2024). Emerging cell and molecular targets for treating mucus hypersecretion in asthma. Allergology International, 73(3), 375-381. https://doi.org/10.1016/j.alit.2024.04.002
Vancouver
Jaramillo AM, Vladar EK, Holguin F, Dickey BF, Evans CM. Emerging cell and molecular targets for treating mucus hypersecretion in asthma. Allergology International. 2024;73(3):375-381. doi:10.1016/j.alit.2024.04.002
BibTeX
@article{Jaramillo2024,
author = {Jaramillo, Ana M and Vladar, Eszter K and Holguin, Fernando and Dickey, Burton F and Evans, Christopher M},
title = {Emerging cell and molecular targets for treating mucus hypersecretion in asthma},
journal = {Allergology International},
year = {2024},
volume = {73},
number = {3},
pages = {375--381},
doi = {10.1016/j.alit.2024.04.002}
}
EUVIMED